Rybelsus (oral semaglutide)

What Rybelsus is licensed for

Rybelsus treats adults with type 2 diabetes whose blood glucose is not controlled well enough by diet and exercise. The patient leaflet on the EMC describes use on its own when metformin cannot be used, or with other diabetes medicines. The MHRA guidance on GLP-1 medicines lists Rybelsus with Ozempic as licensed for diabetes only.

Rybelsus was the first semaglutide tablet in the UK. Since June 2026 a second semaglutide tablet, the Wegovy pill, has been licensed for weight management. The two share an active ingredient and a manufacturer, which makes selection errors more likely.

How the tablet is taken

Oral semaglutide is absorbed only when the stomach is empty. The Rybelsus leaflet tells patients to:

• take the tablet on an empty stomach, after fasting for at least eight hours
• swallow the tablet whole with a sip of water, up to 120 ml, without splitting, crushing or chewing
• wait at least 30 minutes before eating, drinking or taking other tablets

These rules affect other medicines too. A patient who takes levothyroxine or other morning tablets needs a plan for timing, agreed with the prescriber or pharmacist. Ask how the patient fits Rybelsus into the morning before you assume a lack of effect means a need for a change. Dose decisions belong to the prescriber and the Summary of Product Characteristics (SmPC).

Selection and dispensing risks

Three products now share semaglutide and the Novo Nordisk name: Ozempic, Wegovy and Rybelsus, with Wegovy in both injection and tablet form. Rybelsus tablet strengths have also changed over time. Check every Rybelsus prescription against the current SmPC and patient leaflet on the EMC, and confirm the brand, strength and indication before supply.

Say a prescription reads "semaglutide tablets" with no brand and no diagnosis. Contact the prescriber before you dispense. Supplying Rybelsus for weight loss, or Wegovy tablets for diabetes, would put the patient outside the product licence. During the 2023 GLP-1 shortage, the national patient safety alert also told prescribers to avoid switching patients between injections and tablets.

Safety points

• Nausea, diarrhoea, vomiting and constipation are the most common side effects. Severe fluid loss can cause dehydration.
• Low blood sugar is more likely when Rybelsus is used with insulin or a sulfonylurea.
• Diabetic eye disease can worsen. The NHS lists this as a rare serious side effect of semaglutide.
• Acute pancreatitis is rare. Severe stomach pain spreading to the back needs urgent help.
• The MHRA advises stopping semaglutide at least two months before trying to conceive.
• Before surgery or deep sedation, patients should tell the anaesthetist they take a GLP-1 medicine.

The GLP-1 safety guide covers these points for the whole class.

Workplace pressure around an oral GLP-1

Since weight-loss tablets reached the news, some patients ask for Rybelsus by name as a cheaper or easier option for weight loss. Explain the licence, record the request, and refer the patient to a prescriber who can assess licensed weight-management options. The guide to pressure to prescribe gives wording for these conversations.

Pressure can also come from inside a service, for example a request to keep "any semaglutide tablet" in stock to meet demand. The commercial pressure guide and the shortages and demand guide cover how to raise this. Diabetes patients rely on steady supply of Rybelsus, so weight-loss demand should not draw stock away from them.

Reporting side effects

Report suspected side effects, dispensing errors which cause harm, and suspected fake products to the MHRA Yellow Card scheme (opens another website). Concerns about systems which make selection errors more likely go through the steps in the guide to raising patient-safety concerns.

All medicine pages · Ozempic · Wegovy pill · GLP-1 safety